The company produces advanced pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for formulations like tablets, syrups, ointments, etc.
Spot gold increased 0.5% to $2,641.70 per ounce, but was down approximately 0.4% for the week. Last month, prices rose to a record high of $2,685.42.
NSE updates the list of securities banned in the F&O segment daily, depending on the MWPL thresholds.
The regulator stated that all participants should refer to the Ministry of Finance's Accessibility Standards.
In a meeting on Thursday, the board approved this fundraising initiative, which will include the issuing of equity shares.
The project involves integrated infrastructure development for 20M, including wide roads, flyovers, minor bridges, and electrical works under the NAINA project.
During the reporting year, the state-owned firm's total operating income increased by 38% year on year to ₹1,630.38 Crore.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
The company will use net proceeds from the IPO towards working capital requirements and other general corporate purposes as well as unidentified inorganic acquisitions.
According to a regulatory filing by Zydus Lifesciences, the USFDA approved Paliperidone extended-release tablets.

IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Reg. No. INM000010940, SEBI RA Regn. No: INH000000248, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.